Lundbeck (OTCMKTS:HLUYY) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Wednesday.
According to Zacks, “H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of pharmaceuticals across the world. Its products are targeted at disorders like depression and anxiety, schizophrenia, insomnia, Huntington’s, epilepsies, Alzheimer’s and Parkinson’s diseases. The Company is involved in the development of new and improved drugs for the treatment of psychiatric and neurological disorders. H. Lundbeck A/S is headquartered in Copenhagen, Denmark. “
Shares of OTCMKTS HLUYY opened at $57.01 on Wednesday. The stock has a market cap of $11,553.24, a price-to-earnings ratio of 34.52, a price-to-earnings-growth ratio of 3.63 and a beta of -0.01. The company has a quick ratio of 1.13, a current ratio of 1.36 and a debt-to-equity ratio of 0.07. Lundbeck has a 1 year low of $46.05 and a 1 year high of $66.67.
H. Lundbeck A/S engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Denmark and internationally. Its products include Abilify Maintena, Brintellix/Trintellix, Cipralex/Lexapro, Northera, Onfi, Rexulti, Sabril, and Xenazine.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lundbeck Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lundbeck and related companies with MarketBeat.com's FREE daily email newsletter.